The EPISODE trial of psychedelic-assisted therapy for ‘treatment-resistant depression’ finds only modest effects, with a few clear responders, but lingering methodological questions.
[read the full story...]
A small proof-of-principle trial suggests MDMA-assisted therapy may be feasible and effective for depression, but open-label design and a highly pre-treated sample urge caution.
[read the full story...]
Psychedelic therapy looks impressive in trials, but when you account for the placebo effect, how does it really compare to antidepressants?
[read the full story...]
Can ketamine help people with treatment-resistant depression, regardless of childhood trauma history? This new study suggests that trauma load and severity may not influence treatment outcomes.
[read the full story...]
Despite psychedelics’ roots in Indigenous and minoritised communities, clinical trials overwhelmingly centre White participants. This review highlights the consequences and asks how research can change.
[read the full story...]
Despite psychedelics’ deep ties with queer culture, research often excludes queer voices. This recent scoping review highlights gaps and shows how inclusive, intersectional methods can transform the field.
[read the full story...]
Experts from across clinical trials, psychotherapy and regulation have been reflecting on the big challenges facing the field of psychedelics and mental health, following a late 2024 webinar hosted by IAMHRF. This new commentary explores where psychedelic mental health treatments might be heading and what needs to happen next.
[read the full story...]
Lorna Staines discusses a recent Swedish cross-sectional study of 16,255 adolescent twins, which looks at the mental health risks of using psychedelics in the real world.
[read the full story...]
Kirsten Lawson summarises a new ‘state of the art review’ in the BMJ which focuses on novel and emerging pharmacotherapy and neuromodulation for people with ‘treatment resistant depression’.
[read the full story...]
In her debut blog, Gabrielle Williams reviews a US study on the safety and effectiveness of ketamine-assisted therapy (a digital intervention combining psychotherapy, journaling and ketamine) for moderate to severe anxiety and depression.
[read the full story...]
